Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Back to dashboard
Company Information
About this company
Key people
Eliot Richard Forster
Independent Chairman of the Board
Dror Bashan
President, Chief Executive Officer, Director
Gilad Mamlok
Chief Financial Officer, Senior Vice President, Treasurer, Company Secretary
Yaron Naos
Chief Operating Officer
Amos Bar Shalev
Independent Director
Shmuel Ben Zvi
Independent Director
Pol F. Boudes
Independent Director
Christian Elze
Independent Director
Click to see more
Key facts
- Shares in issue80.57m
- EPICPLX
- ISINUS74365A3095
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$199.82m
- Employees226
- ExchangeNyse American LLC
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.